1. Home
  2. KALV vs RNP Comparison

KALV vs RNP Comparison

Compare KALV & RNP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KalVista Pharmaceuticals Inc.

KALV

KalVista Pharmaceuticals Inc.

HOLD

Current Price

$26.74

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Cohen & Steers REIT and Preferred and Income Fund Inc.

RNP

Cohen & Steers REIT and Preferred and Income Fund Inc.

HOLD

Current Price

$20.47

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
KALV
RNP
Founded
N/A
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
KALV
RNP
Price
$26.74
$20.47
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$32.60
N/A
AVG Volume (30 Days)
4.5M
78.0K
Earning Date
07-09-2026
01-01-0001
Dividend Yield
N/A
7.94%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$50,000,000.00
N/A
Revenue This Year
$185.42
N/A
Revenue Next Year
$59.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
495.66
N/A
52 Week Low
$9.83
$19.27
52 Week High
$26.85
$22.99

Technical Indicators

Market Signals
Indicator
KALV
RNP
Relative Strength Index (RSI) 74.83 40.03
Support Level $14.56 $19.90
Resistance Level N/A $20.55
Average True Range (ATR) 0.15 0.26
MACD 0.01 -0.06
Stochastic Oscillator 98.60 1.49

Price Performance

Historical Comparison
KALV
RNP

About KALV KalVista Pharmaceuticals Inc.

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

About RNP Cohen & Steers REIT and Preferred and Income Fund Inc.

Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances. The Fund seeks to achieve its objectives through a portfolio of income producing common stock issued by REITs and preferred and other debt securities.

Share on Social Networks: